BridgeBio Pharma (BBIO) Research & Development (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Research & Development for 7 consecutive years, with $116.4 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 10.69% to $116.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $452.0 million through Dec 2025, down 10.76% year-over-year, with the annual reading at $452.0 million for FY2025, 10.76% down from the prior year.
- Research & Development hit $116.4 million in Q4 2025 for BridgeBio Pharma, up from $112.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $141.0 million in Q1 2024 to a low of $90.9 million in Q4 2022.
- Historically, Research & Development has averaged $113.2 million across 5 years, with a median of $112.2 million in 2025.
- Biggest five-year swings in Research & Development: skyrocketed 79.64% in 2021 and later dropped 25.61% in 2022.
- Year by year, Research & Development stood at $122.2 million in 2021, then decreased by 25.61% to $90.9 million in 2022, then surged by 43.26% to $130.2 million in 2023, then increased by 0.1% to $130.4 million in 2024, then dropped by 10.69% to $116.4 million in 2025.
- Business Quant data shows Research & Development for BBIO at $116.4 million in Q4 2025, $112.9 million in Q3 2025, and $111.2 million in Q2 2025.